These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8748619)

  • 21. [Optimisation of treatment of Parkinson's disease with levodopa].
    Białecka M; Adamiak U; Gawrońska-Szklarz B
    Neurol Neurochir Pol; 2009; 43(5):446-59. PubMed ID: 20054747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irregular gastrointestinal drug absorption in Parkinson's disease.
    Nyholm D; Lennernäs H
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):193-203. PubMed ID: 18248312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox.
    Ugwoke MI; Agu RU; Kinget R; Verbeke N
    Boll Chim Farm; 2003 Oct; 142(8):315-8. PubMed ID: 15040458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
    Krankenpfl J; 2005; 43(7-10):241. PubMed ID: 16515311
    [No Abstract]   [Full Text] [Related]  

  • 30. Apomorphine-induced penile erections in Parkinson's disease.
    O'Sullivan JD; Hughes AJ
    Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of apomorphine in the treatment of Parkinson's disease.
    Boyle A; Ondo W
    CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
    Harder S; Baas H
    Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
    Baas H; Harder S; Demisch L; Bürklin F; Stecker K; Fischer PA
    J Neural Transm Suppl; 1995; 46():367-79. PubMed ID: 8821072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
    Junginger HE
    Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S57-75. PubMed ID: 12460716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    Isr J Med Sci; 1996 Dec; 32(12):1224-7. PubMed ID: 9007159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.